{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:21Z","timestamp":1789578141694,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Waldenstr\u00f6m macroglobulinaemia (WM) is a rare and incurable lymphoma. Comparative studies evaluating the efficacy of primary therapy in symptomatic WM patients have not been performed. In this study, we compared response and survival outcomes in WM patients who received primary therapy with cyclophosphamide\u2010dexamethasone\u2010rituximab (CDR), bortezomib\u2010dexamethasone\u2010rituximab (BDR) and bendamustine\u2010rituximab (Benda\u2010R), as well as maintenance rituximab following primary therapy. Analyses were adjusted for relevant clinical factors associated with response and survival. Maintenance rituximab was analysed as a time\u2010varying covariate. Our study included 182 patients, of which 57 (31%) received Benda\u2010R, 87 (48%) BDR and 38 (21%) CDR; 116 (64%) received maintenance rituximab. The median time to best response was shorter for Benda\u2010R and BDR than CDR (18, 20 and 30\u00a0months, respectively). Benda\u2010R and BDR were associated with better median progression\u2010free survival (PFS) than CDR (5\u00b75, 5\u00b78 and 4\u00b78\u00a0years, respectively), and better 10\u2010year overall survival rates (OS; 95%, 96% and 81%, respectively). Maintenance rituximab was associated with higher rates of major response (97% vs. 68%), and better median PFS (6\u00b78\u00a0years vs. 2\u00b78\u00a0years) and 10\u2010year OS rate (84% vs. 66%) when compared to not receiving maintenance. Benda\u2010R, BDR and maintenance rituximab associate with higher response rates and longer survival in WM patients than CDR and no maintenance, respectively.<\/jats:p>","DOI":"10.1111\/bjh.15148","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T05:28:01Z","timestamp":1519277281000},"page":"77-85","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr\u00f6m macroglobulinaemia"],"prefix":"10.1111","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Gustine","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Meid","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni E.","family":"Dubeau","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Severns","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Xu","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary R.","family":"Hunter","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6154","authenticated-orcid":false,"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Dana\u2010Farber Cancer Institute Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30137"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13264"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.9926"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-503862"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30632-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742411"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001714043"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20658"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647420"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50038"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174961"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0126"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14828"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14826"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood.V120.21.2739.2739","article-title":"Bendamustin\u2010rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenstrom's macroglobulinemia: results from a prospective, randomized, Multicenter Study (StiL NHL 7\u20102008 \u2010MAINTAIN\u2010; ClinicalTrials.gov Identifier: nCT00877214)","volume":"120","author":"Rummel M.J.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh403"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi022"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08750.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V126.23.1833.1833","article-title":"Long\u2010term outcome of a prospective study of bortezomib, dexamethasone and rituximab (BDR) in previously untreated, symptomatic patients with Waldenstrom's macroglobulinemia","volume":"126","author":"Treon S.P.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_7_28_1","first-page":"2767","article-title":"Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom's macroglobulinemia","volume":"130","author":"Treon S.P.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-454355"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13897"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15148","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:47:01Z","timestamp":1694368021000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/bjh.15148"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15148","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"2017-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}